Browse the evidence

GIP receptor antagonism promotes weight loss and protects against diet-induced obesity, potentially by enhancing leptin sensitivity in the hypothalamus and reducing lipid storage in adipose tissue.

Research indicates that blocking the GIP receptor (antagonism) can also lead to weight loss, possibly by improving how your body responds to leptin and reducing fat storage. This is an emerging area of treatment, with some drugs in clinical trials combining GIP antagonism with GLP-1 agonism for enhanced effects.

Higher starch intake is associated with lower levels of specific plasma proteins (adrenomedullin, IL1ra, FABP4, leptin, CCL20) that are themselves positively associated with increased CVD and mortality risk.

This finding suggests that moderate starch intake may help regulate inflammatory and adiposity-related proteins. However, since the association weakened after adjusting for BMI, maintaining a healthy weight is likely the primary driver of these benefits.

Off-label prescribing of semaglutide (Ozempic) for weight loss causes significant supply shortages for patients with type 2 diabetes who require the medication for its FDA-approved indication.

If you are considering Ozempic for weight loss, understand that it is a serious medication, not a cosmetic shortcut. It works by mimicking hormones that regulate hunger, but stopping it often leads to significant weight regain. Be aware that high demand for off-label use has caused shortages for people who need it for diabetes, so discuss ethical access and long-term sustainability with your doctor before starting.

GLP-1 receptor agonist therapy improves tear production and tear film stability in patients with type 2 diabetes compared to non-GLP-1 RA therapies.

If you have Type 2 Diabetes and are considering or using GLP-1 RAs (like semaglutide or dulaglutide), this research suggests these medications might actually help keep your eyes moist and stable compared to other diabetes drugs. While this doesn't replace standard dry eye treatments, it is a potential benefit to discuss with your doctor, especially if you suffer from dry eye symptoms.

Network pharmacology analysis suggests that the synergistic mechanism of combined exercise and medication involves the IL1B-STAT3 inflammatory axis and SIRT1/CD36 lipid metabolism network.

This is a mechanistic hypothesis. It suggests that combining exercise and medication may work by reducing inflammation (IL1B-STAT3) and improving lipid metabolism (SIRT1/CD36).

Dual GLP-1/glucagon agonists (e.g., cotadutide, pemvidutide) provide greater reductions in liver fat and fibrosis markers than GLP-1 mono-agonists, likely due to glucagon-mediated mitochondrial turnover and glycogenolysis.

If GLP-1 mono-agonists (like semaglutide) are not enough, dual agonists (like cotadutide or pemvidutide) may offer greater liver fat reduction and fibrosis improvement. However, these drugs are more complex and may cause more side effects. They are currently in clinical trials and not yet standard care. Discuss with your hepatologist if you are a candidate for these newer agents, especially if you have significant liver fat but stable diabetes.

Semaglutide use is associated with a high incidence of gastrointestinal adverse events, including nausea, vomiting, diarrhea, and constipation, with signal strength varying by clinical priority and time-to-onset.

If you are taking semaglutide, expect gastrointestinal side effects like nausea, vomiting, or diarrhea, especially when starting or increasing the dose. These are common and often decrease over time. Discuss starting with a lower dose and titrating slowly with your provider to improve tolerance. Ensure you stay hydrated and eat smaller, bland meals if symptoms occur.

Six months of once-weekly GLP-1 analogue (semaglutide) therapy restores natural killer (NK) cell effector function (cytotoxicity and cytokine production) in people with obesity, independent of weight loss.

For people with obesity, GLP-1 therapy (like semaglutide) may strengthen the immune system's ability to fight viruses and cancer, independent of how much weight is lost. This suggests benefits beyond just metabolic health.

GLP-1 therapy restores NK cell metabolism by upregulating the CD98-mTOR-glycolysis axis, which is critical for NK cell cytokine production.

GLP-1 therapy helps fix the 'metabolic engine' of immune cells (NK cells) in obese individuals, allowing them to produce necessary defense chemicals (cytokines) more effectively.

GLP-1 receptor agonists should be discontinued prior to metabolic bariatric surgery to prevent delayed gastric emptying and aspiration pneumonia during anesthesia.

If you take GLP-1 medications (like Ozempic or Saxenda) and are having bariatric surgery, you MUST stop them before the procedure. Daily users should stop on the day of surgery; weekly users should stop one week prior. This prevents life-threatening aspiration pneumonia.

GLP-1 receptor agonists (GLP-1RAs) exert immunoregulatory effects by promoting the polarization of macrophages and microglia from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype, thereby reducing neuroinflammation and systemic inflammatory markers.

If you are using a GLP-1RA (like semaglutide or liraglutide) for diabetes or weight loss, understand that it may also be helping to lower systemic inflammation by shifting your immune cells toward a less inflammatory state. This is not just a side effect but a direct mechanism of action on your immune system.

GLP-1RAs modulate T cell differentiation by reducing the proportion of pro-inflammatory Th17 cells and increasing regulatory T cells (Tregs), thereby improving immune tolerance and reducing inflammation in conditions like psoriasis and colitis.

For those with autoimmune conditions, GLP-1RAs may help rebalance your immune system by reducing inflammatory T cells and boosting regulatory ones. This could potentially complement standard treatments by addressing the underlying immune imbalance.

GLP-1RAs reduce innate allergic inflammation and eosinophilia by inhibiting the activity of Group 2 Innate Lymphoid Cells (ILC2s) and reducing the production of type 2 cytokines (IL-5, IL-13).

If you have allergic asthma, GLP-1RAs might help reduce the specific allergic inflammation driven by innate immune cells, potentially easing symptoms beyond just metabolic benefits.

GDF15, a member of the TGF-β superfamily, acts as a central regulator of appetite and a potential treatment for obesity by reducing food intake and stimulating lipolysis.

GDF15 is a hormone that reduces food intake and increases fat burning. Research suggests it could be a future treatment for obesity, offering a different mechanism from current drugs.

GLP-1-based therapies and SGLT2 inhibitors provide protective effects on the coronary microvascular compartment in diabetic patients, addressing coronary microvascular dysfunction (CMD).

If you have diabetes and signs of heart issues like chest pain or shortnessess of breath without blocked arteries (CMD), ask your doctor about GLP-1 agonists or SGLT2 inhibitors. These drugs are increasingly recognized to protect the small blood vessels in the heart, beyond just lowering blood sugar.

Endogenous GLP-1 secretion is stimulated by specific nutrient-sensing mechanisms in intestinal L-cells, including SGLT1 and KATP channels for carbohydrates, FFA1 and GPR119 for fats, and Pept1 and CaSR for proteins.

This paper explains the biological 'sensors' in your gut that trigger GLP-1 release when you eat carbs, fats, and proteins. While understanding these mechanisms (like SGLT1 for sugar or GPR119 for fat) is crucial for drug development, there are currently no standard dietary protocols to specifically target these receptors for therapeutic GLP-1 elevation. The paper highlights that while animal models show clear results, human applicability is still being researched.

Long-term adherence to GLP-1 receptor agonist therapy significantly reduces the risk of major adverse liver outcomes (MALO) in patients with chronic liver disease and type 2 diabetes, whereas intention-to-treat analysis shows no significant benefit due to high discontinuation rates.

If you have chronic liver disease and type 2 diabetes, GLP-1 medications (like semaglutide or liraglutide) can significantly lower your risk of serious liver complications (like cirrhosis or liver cancer) over 10 years, BUT only if you keep taking them. Half of the patients in this study stopped taking the drug, which erased the benefit in the general group. To get the liver protection, you must manage side effects and stay on the treatment long-term.

Semaglutide is associated with a significantly higher reporting odds ratio for gastrointestinal adverse drug reactions (GADRs) compared to liraglutide, with a later median time-to-onset (7 days vs 4 days).

If you are considering GLP-1 weight loss drugs, know that semaglutide is associated with a higher reporting rate of stomach issues (nausea, vomiting, etc.) and a later onset of these symptoms compared to liraglutide. To minimize side effects, insist on a slow dose titration starting at the lowest dose. If semaglutide causes intolerable side effects, discuss switching to liraglutide, which may have a different gastrointestinal risk profile.

A single subcutaneous injection of a biomimetic hydrogel depot containing GLP-1 receptor agonists (semaglutide or liraglutide) sustains therapeutic drug exposure for approximately 42 days in rats, enabling a once-every-4-months dosing regimen in humans that maintains blood glucose and weight management comparable to daily or weekly injections.

This research suggests that a new type of injection using a hydrogel depot could allow people with type 2 diabetes to take their GLP-1 medication (like semaglutide or liraglutide) only once every four months instead of daily or weekly. In animal studies, this single shot kept blood sugar and weight under control just as well as taking the drug every day. While the technology is promising, it is currently only proven in rats, so human dosing and safety are not yet confirmed.

In lean individuals with low baseline triglycerides, carbohydrate-restricted diets cause elevated LDL-C and HDL-C through increased hepatic VLDL secretion and lipoprotein lipase (LPL)-mediated turnover, rather than through atherogenic dyslipidemia mechanisms.

If you are lean and keep your triglycerides low while eating low-carb, your LDL might rise significantly. This paper suggests this is likely due to efficient fat burning (high LPL activity) rather than the dangerous type of high cholesterol seen in obesity/diabetes. Monitor your triglycerides and HDL; if TG is low and HDL is high, the high LDL may be less concerning, though long-term cardiovascular outcomes in this specific group require more research.

GLP-1 receptor agonists (GLP-1RAs) activate brown adipose tissue (BAT) in humans, increasing its metabolic volume and glucose uptake, although this activation does not necessarily translate to increased fat fraction reduction or resting energy expenditure in all clinical contexts.

If you are using a GLP-1 medication like semaglutide or liraglutide, part of its benefit comes from activating your brown fat, which burns energy as heat. This happens alongside reduced appetite. While this doesn't always show up as 'less fat' in immediate scans, it contributes to better metabolic health and weight management. Stick with the treatment as prescribed.

Type 2 diabetes mellitus impairs weight reduction in obese patients primarily through energy conservation (reduced glucosuria), hyperinsulinemia-driven lipid storage, and the use of obesogenic anti-diabetes medications.

If you have Type 2 Diabetes and struggle to lose weight, it is likely not just a willpower issue. Your body is conserving energy because your blood sugar is better controlled (less sugar peed out), and medications like insulin or sulfonylureas may be actively promoting fat storage. Discuss switching to diabetes medications that support weight loss (such as GLP-1 agonists or SGLT2 inhibitors) with your doctor, as these can help overcome these physiological barriers.

Obesogenic anti-diabetes medications, specifically those that increase insulin exposure (insulin, sulfonylureas, meglitinides), actively promote weight gain and hypoglycemia, which necessitates increased caloric intake and impairs weight loss.

If you are taking insulin, sulfonylureas, or meglitinides, these drugs may be making weight loss impossible by causing low blood sugar (hypoglycemia). To prevent lows, you may be eating extra carbs. Ask your doctor about switching to diabetes medications that do not cause hypoglycemia or weight gain, such as GLP-1 agonists or SGLT2 inhibitors.

Semaglutide administration reduces visceral fat accumulation and improves glucose intolerance in obese mice by downregulating key lipogenic proteins (CD36, FABP5, ACSL, PLIN2) in epididymal white adipose tissue.

In this mouse study, semaglutide reduced fat mass by altering how fat cells store and process lipids, specifically by downregulating proteins like CD36 and PLIN2. This suggests that GLP-1 therapies may have direct peripheral effects on fat tissue metabolism, not just central appetite control. For humans, this supports the use of GLP-1 agonists for obesity management, though human dosing and response may vary.